Compare PAR & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAR | EVMN |
|---|---|---|
| Founded | 1968 | 2020 |
| Country | United States | United States |
| Employees | N/A | 48 |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.6M | 717.5M |
| IPO Year | 1995 | N/A |
| Metric | PAR | EVMN |
|---|---|---|
| Price | $15.92 | $24.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $33.20 | ★ $43.88 |
| AVG Volume (30 Days) | ★ 1.3M | 475.3K |
| Earning Date | 05-07-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $455,547,000.00 | N/A |
| Revenue This Year | $9.82 | N/A |
| Revenue Next Year | $11.27 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 30.16 | N/A |
| 52 Week Low | $11.59 | $13.89 |
| 52 Week High | $72.15 | $33.20 |
| Indicator | PAR | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 58.55 | 59.60 |
| Support Level | $12.50 | $21.32 |
| Resistance Level | $16.41 | $25.50 |
| Average True Range (ATR) | 1.01 | 1.54 |
| MACD | 0.18 | 0.54 |
| Stochastic Oscillator | 80.81 | 74.56 |
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). Its product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.